2021 Managed Healthcare Executive® Pharmacy Survey: What Federal Policy Will Most Likely Occur in 2021, Which Will Curb Drug Prices?
In this final part of the MHE 2021 Pharmacy Survey, participants share their thoughts on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year. MHE's annual pharmacy survey had over 225 respondents.
In this final part of the 2021 Pharmacy Survey slideshow series, participants shared their opinions on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year.
The majority of respondents (23%) said requiring PBMs to reimburse pharmacies at or above pharmacies’ drug acquisition costs, is a policy they favor most as a way to curb drug prices. Other policies most favored were: restricting the use of copay accumulator programs (20%), putting limits on drug price increases (20%), negotiating Medicare drug prices (12%), putting limits on out-of-pocket costs for Medicare beneficiaries (11%), mandating transparency in coverage rules (8%), and
linking Medicare Part B drug prices to prices paid in other countries (the Most Favored Nation model) (7% ).
Related: 2021 Managed Healthcare Executive® Pharmacy Survey: Drugs New to the Market Most Likely to Reduce Morbidity, Mortality
When asked which federal policy will most likely occur in 2021, most respondents (29%) favored towards limiting on out-of-pocket costs for Medicare beneficiares. Following policies were: Most Favored Nation model for Medicare Part B drugs (23%), federal limits on drug price increase (21%), none of the above (10%), CMS negotiating Medicare drug prices (9%), and no substantial federal policy change will occur (9%).
Just over 225 people responded to our online survey between April 5 and May 10.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
